Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Anergis S.A.
DescriptionBirch pollen allergy vaccine containing contiguous overlapping peptides (COP) derived from birch pollen
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsDesensitization for moderate to severe allergies to birch pollen
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today